Trimipramine

Anticholinergic

Blocks acetylcholine. Can cause a fast heart rate, dry mouth, reduced sweating and heat intolerance, and confusion, more so at high doses or in combination. Sources [1]

Blocks 5-HT2A (may blunt effects)

Blocks the 5-HT2A receptor, the main receptor psilocybin acts through. Can reduce or block the psilocybin effect. Sources [3]

QT-prolonging

Lengthens the QT interval on an ECG, a measure of the heart’s electrical recovery between beats. A long QT raises the risk of a dangerous heart rhythm, more so with other QT-prolonging drugs or low potassium or magnesium. Sources [2]

Lowers seizure threshold or carries seizure risk

Makes a seizure more likely, or has been linked to seizures. Sources [1]

Serotonergic

Increases serotonin activity, for example by blocking its reuptake or releasing it. Psilocybin acts on serotonin receptors, so effects can add together. With antidepressant use, the psilocybin response can be weaker. Sources [1]

No condition named in state rules is linked to this medication.

1. TRIMIPRAMINE MALEATE CAPSULES, 25 MG, 50 MG and 100 MG Rx Only · FDA label (DailyMed)
2. Preston CL (ed). Stockley’s Drug Interactions, 11th ed. Pharmaceutical Press, 2016., p. 286 — class: tricyclics in QT-prolonging drug table
3. NIMH Psychoactive Drug Screening Program (PDSP) Ki Database, University of North Carolina. Roth BL et al. (per-entry query link; primary references in note) — 5-HT2 Ki 19.5 nM rat cortex, racemate (Gross 1991)

Report an error in this record →